Literature DB >> 3087280

Comparative in vitro antimicrobial activity of carumonam, a new monocyclic beta-lactam.

B R Smith, J L LeFrock, R V McCloskey, J B Donato, S J Weber, W S Joseph.   

Abstract

The antimicrobial activity of carumonam (formerly RO-17-2301), a monocyclic beta-lactam antibiotic, was compared with those of aztreonam, cefotaxime, cefoperazone, ceftazidime, piperacillin, and gentamicin against 455 bacterial isolates. Carumonam did not possess activity against gram-positive cocci and was generally comparable to aztreonam and ceftazidime for most gram-negative bacilli. However, carumonam was the most active beta-lactam against gentamicin-resistant Pseudomonas aeruginosa strains (90% MIC, 8 micrograms/ml).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3087280      PMCID: PMC176408          DOI: 10.1128/AAC.29.2.346

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  2 in total

1.  In vitro activities of Ro 17-2301 and aztreonam compared with those of other new beta-lactam antibiotics against clinical isolates of Pseudomonas aeruginosa.

Authors:  W W Ng; P Y Chau; Y K Leung; D M Livermore
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

2.  Single-dose pharmacokinetics of Ro 17-2301 (AMA-1080), a monocyclic beta-lactam, in humans.

Authors:  E Weidekamm; K Stoeckel; H J Egger; W H Ziegler
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

  2 in total
  1 in total

1.  Carumonam versus ceftazidime for urinary tract infections.

Authors:  H Edelstein; S Oster; K Cassano; R McCabe
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.